Huge uptick block at the close

This scam still being run? Amazing

RLMD about to surface $40 next stop then 48 quickly
Needed the close above 35.25 today

Jeffries reiterates buy w target of $75 ( $175 potentially)

https://javatar.bluematrix.com/sellside/EmailDocViewer?encrypt=b56fc968-08b0-4333-8db0-68a8e28cc8ee&mime=html&co=Jefferies&id=robert.dicristina@theupsidegroup.com&source=mail

Decisive Day: broke 200 day MAV
Possibly drop to 34-35 support

https://stockcharts.com/h-sc/ui?s=RLMD

Expected RLMD to drop to 36-37 (it hit 38.5) but bounced to 43.

A close above 45.5 would repair the chart trend.

https://stockcharts.com/h-sc/ui?s=RLMD

The chart seems to show it could drop again but I’m not selling,
Oppenheimer just issued a buy w price target of $75. All 5 reports indicate the revenues from their drug will be 1b + within a few years. Fibonacci indicates 71 after closing above 50.

I’ve predicted it will hit $500 soon after REL-1017 is approved and sales begin. It’s the safest, cheapest and fastest acting drug for depression yet developed. Missed my July 4th target. BTD would help.

I’m riding this like Ahab rode Moby Dick but hoping for a better ending.

selling 10% at $100 this year, 10% at $150 next year then buying puts just before the phase 3 results are released, kissing that put $ goodbye and selling the balance at $3,000 in 4 years ( based on Goldman’s and others revenue estimates)

Good close just above the 50 day moving average, repairing the chart pattern

Relmada on Russell 3000 and 2000 indexes
Causing 1.5mm+ shares TO BE put away for at least a year
25% move on BTD

Strange day
‘Always expect the unexpected’ —Roald Dahl
1.5mm shares + crossed and put away in the Russell 2000 and 3000 funds
Market didn’t help, a delicate transaction. Jeffries probably queried all large holders seeking any weak hands for the cross....it’s a good thing, shares out of the float for at least a year.
AXSM got a nice boost from Breakthrough Therapy Designation....

Former FDA CRO said recently ‘judging from the quality of the people they’re hiring RLMD looks like they are playing the long game’ meaning they are gearing up to take REL 1017 to approval not selling out


RTW Investments filed 13G showing additional 271.13K shares of RLMD purchased. Brings them up to 1.26M 8.26%

In the Russell 3000, waiting on 2000

register for live Jeffries Relmada presentation today at 10 Central

http://wsw.com/webcast/jeff126/register.aspx?conf=jeff126&page=rlmd&url=http://wsw.com/webcast/jeff126/rlmd/index.aspx

Use any company name
Rebroadcast available

Ask them.
Top notch people coming on board now. Dr. V served the company well and remains a stockholder

Probably done at a much higher price
‘$100 by July 4th’
Good planning

Avoro Buys 7.7% of RLMD 13 F filed yesterday

https://avorocapital.com/

Jeffries announced a $75mm market offering

https://ih.advfn.com/stock-market/NASDAQ/relmada-therapeutics-RLMD/stock-news/82474251/prospectus-filed-pursuant-to-rule-424b5-424b5

after the close today the announcement about RLMD being added to the Russell indexes should be released. Best estimate I’ve seen is that would require the funds to add approximately 1.5mm shares sometime in June. With < 20mm AIO today and 70% closely held it should be... positive

Sun Trust Robinson Humphries initiates coverage w a buy target price $75
The Bible says you only need 3 witnesses to prove truth, we’ve got 4
If it doesn’t close above 40 it’s the overall market or some delay at FDA, expected.

https://www.sciencetimes.com/articles/25473/20200427/look-sky-whale-spotted-over-texan-skies-science-pareidolia-explained.htm

It’s an omen

Thar she blows !

https://blog.tipranks.com/goldman-sachs-2-stocks-that-could-climb-over-60/

Russell 2000 ranking day is May 8, 2020. RLMD should get included...would result in some add'l share purchases in June by funds that track the Russell 2000.

And tomorrow is a new moon!
BTD? That would be interesting

Ahab the chartist:

Goldman Sachs issues buy report on RELMADA price target $64

My target still $500 in 3 years

RLMD will broach on the new moon in April
(23rd)
Seems to have east coast sellers in the morning and west coast buyers by early afternoon...every day
Informed speculation that REL 1017 could become the Standard of Care for TRD supports my estimates if $500-$1000/ share

20,000 buyer at the close bumped it up $1.25/ share hmmm

Strange day, 5 up days MACD breakout ( lower right crossing) didn’t happen.
In sympathy w AXSM and SAGE ? No relation to RLMD

https://stockcharts.com/h-sc/ui?s=RLMD

Is BTD delayed by Wuhan400? probably,
market decline NOT due to the presidential press conference today, Azar, Birx, Fauchi and Trump kicked ass.

Is it about the possibility of losing the Senate? NC’s Burr ( gotta love his rebuttal - his sales came BEFORE the market decline began- YGBSM ?!?) and GA’s Loefflers stupid inside trades? Loeffler the Trophy Wife Senator‘s hubby is chairman of the NYSE BUT they didn’t discuss her secure briefing? YGBSM Easy to prove it wasn’t her 3 Blind Mice doing it.
20 year$ her senior but a hand$OME dude

NEW MOON MONDAY

Noles:
Smith &Nephew acquisition of Osiris implies what value to MDXG?
Lost 1/2 million in last week on RLMD but not selling, Rockefellers paid $30 in December

FSU’72 so long ago we called it ‘half ass U’ lived it what became known as the Burt Reynolds athletic dorm Stadium apartments, so many VWs in the pool they cemented it in

People suddenly worried about 2.5 million new AUTHORIZED shares?
“don’t worry about dilution, the 2.5 million additional AUTHORIZED shares will probably be ISSUED in a 2.5 million share secondary offering at $75 in 4 months OUTSTANDING!!”

Are you not game for the hunt for the white whale Starbuck ? My fate is sealed

Correction: Monday the 23rd of April

Moby Dick was predicted to arrive at Bikini on the -new moon- in April, this year that’s Monday the 23rd, if this was an omen then that’s the day RLMD blows

strange coincidence? sent this text to the Bull of Durham my 40 year chartist buddy after watching Moby Dick for the umpteenth time ( it’s a genetic thing)

“Ahab was a technical chartist, Relmada blows April 22, the full moon, at Bikini!”

RLMD long pep talk:

https://https://youtu.be/O5Xu5druM94.be/O5Xu5druM94

I’m riding RLMD like Captain Ahab rode Moby Dick

“Residual price action. Gap filled. Awaiting a new formation. No call at this point.”
—-Mike, The Bull of Durham trusted chartist
“Important pesky gap, good thing it filled, if it doesn’t hold 33 it’s headed lower, 24 next support”
Under $30 you will be paying less than the financiers of Intel and Apple
No word yet on BTD, effect of BTD widely varied for biotech stocks in the past, muted today in these market conditions
According to Dean Koontz 1981 novel Eyes of Darkness the Wuhan400 man made virus will be released in ‘2020’’
Snopes points out it’s not accurate; Wuhan400 has a shorter incubation period and was 100% fatal.
Thanks Snopes!
Later editions call it the Gorky Virus and put the lab in Russia (?)

https://stockcharts.com/h-sc/ui?s=RLMD
$33 is $10 down from 50 day MAV, $10 up from 200 day
Riding it out like Captain Ahab on Moby Dick

Guggenheim hosting RLMD road show DALLAS tomorrow
Boston today,

@Relmada Therapeutics: A Promising Depression Focused Player For 2020
Feb. 17, 2020 10:08 AM ETRelmada Therapeutics, Inc. (RLMD)AXSM, VTGN2 Comments
Summary

Relmada Therapeutics' lead asset, REL-1017 can be a game-changer in depression indication.
The company has sufficient funds to sustain its operations.
Investors should consider risks such as business concentration risk, R&D failure risk, and commercial uptake uncertainties.

Today, we will study why Relmada Therapeutics (NASDAQ:RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020.”
REL-1017 can offer a more effective yet safer treatment option for TRD patients
In 2017, there were 17.3 million MDD (major depressive disorder) patients in the U.S. Of these, 10% - 30% suffer from TRD (treatment-resistant depression). NMDA antagonists are fast emerging as a potent class of drugs in the depression indication. REL-1017 can prove to be equal or even superior to the much-touted Ketamine with a stronger safety profile as an antidepressant for TRD patients.

....Like Ketamine, D-methadone seems to possess NMDA antagonist properties which have an anti-depressant effect. This was seen in three animal models of depression. The drug's Phase 1 trial also demonstrated a favourable safety and tolerability profile of the drug. D-methadone has not demonstrated adverse events associated with traditional opioid or ketamine at the expected therapeutic doses. D-methadone is an isomer of racemic methadone.

Normally, racemic methadone is associated with common opioid side effects such as anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhoea, drowsiness, and others. Published literature shows that left or Levo isomer, l-methadone, is largely is related to opioid activity, while the right or Dextro isomer, d-methadone, has less of that activity.



If approved, Dextromethadone may be a more convenient treatment option in terms of its dosing regimen and route of administration.

REL-1017 has demonstrated robust efficacy and safety in Phase 2 trial
On October 15, Relmada Therapeutics announced positive topline data from Phase 2 REL-1017-202, study evaluating two dosages, 25 mg once a day and 50 mg once a day, of REL-1017 as an adjunctive treatment option for TRD patients....

RLMD very bullish seeking alpha (!) article
Jeffries analyst Tsai excepts 50-100% gain if RLMD receives Breakthrough status.

REL 1017 worth $1-2 billion if approved for TRD alone ($71-$140/share assuming 14mm shares OI&S)

Tiedmann (1.5%) Parsons (2.5%) and VHCP (5.2%) buy chunks of RLMD, soon there won’t be any stock left

Just don’t know IF RLMD
has applied for BTD or WHEN they may apply, if they haven’t already.
Company doesn’t leak, they should run the NSC

Jeffries wrote Breakthrough Designation could come in ‘1st quarter’
I thought it would be later

my friend the chartist said it had to back fill to 35-35.5 to resume a strong uptrend, I forgot his warning when it started to run. When will I ever learn to trade?

Jeffries 41 page buy recommendation today
Now all 3 co managers have published buy reports as expected
After final phase 2 meeting ( first half on 2020) w FDA REL 1017 may get Breakthrough Therapy designation
Watch for large block trades above the offer, whoever it is they haven’t filed a 13D yet
Chart looks like 55-61 short term